Cognition Therapeutics, Inc. (CGTX) Files for Up to $50M IPO

Cognition Therapeutics, Inc. (NASDAQ: CGTX) filed for up to $50,000,000 IPO.

The company describes itself as: "We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system, or CNS, and retina. Currently available therapies for these diseases are limited, with many diseases having no approved therapies or treatments. Our goal is to develop disease modifying treatments for patients with these degenerative disorders by initially leveraging our expertise in the σ-2 (sigma-2) receptor, or S2R, which is expressed by multiple cell types, including neuronal synapses, and acts as a key regulator of cellular damage commonly associated with certain age-related degenerative diseases of the CNS and retina. We believe that targeting the S2R complex represents a mechanism that is functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases."

B. Riley Securities will serve as sole underwriter.

You May Also Be Interested In

• Karman Line Acquisition prices $200M IPO on Nasdaq
• GoPro promotes CFO Brian Tratt to senior vice president role
• Hyperscale Data declares preferred stock dividends for September